Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine in major depressive disorder and pain
NCT00191919Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) and pain comparing Duloxetine 60mg with Placebo (2 arms). Primary endpoint: Brief Pain Inventory at 8 weeks. Started May 2005; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)pain
Beyond the preview
Go deeper on NCT00191919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191919.